DIRECT MEDICAL COST OF COMPLICATIONS IN PATIENTS WITH NON VALVULAR ATRIAL FIBRILLATION NVAF AT A PRIVATE HOSPITAL IN VENEZUELA

Author(s)

Fernandez Y1, Chiquinquira K2, Garrido Lecca S3
1Universidad Central de Venezuela Facultad de Medicina Escuela de Salud Publica, Caracas, Venezuela, 2Unesar Clinica Santa Sofía, Caracas, Venezuela, 3Bristol-Myers Squibb, Lima, Peru

OBJECTIVES: Estimate direct medical costs of selected acute complications in patients with non-valvular atrial fibrillation (NVAF) at a private hospital “Clínica Santa Sofía” in Venezuela.  METHODS: The hospital´s Medical Statistics Department was used to identify the study population. CIE-10 codes were used to identify patients with NVAF and select complications of AF.  Complications of interest are: ischemic stroke, hemorrhagic stroke, systemic embolism, myocardial infarction, gastrointestinal hemorrhage and non-neurological hemorrhage.   All cases from 2012 -2013 meeting the inclusion criteria were reviewed. Patient level data from clinical charts was extracted to estimate resource utilization per patient per event. Costs were estimated using the hospital’s 2014 tariffs and expressed per patient in 2014 Bolívares Fuertes (BsF).   RESULTS: Mild and moderate ischemic stroke costs were estimated at BsF. 79,114 (SD 103,903), BsF 90,266 (SD 97,934). One case of mild, and one case of moderate ischemic stroke consumed high healthcare resources in this study population. Only one case of severe fatal ischemic stroke was identified and costs were estimated at BsF 14,143. No hemorragic stroke events were collected. Systemic embolism and myocardial infarction costs accounted for BsF 79,846 and BsF 36,332 (SD 13,865) respectively. Gastrointestinal hemorrhage was estimated at BsF 16,229 (SD 1,841) and only 1 event of non-neurological hemorrhage was collected and costs estimated at BsF 8,864.  CONCLUSIONS: Direct medical costs for NVAF patients at this private hospital increase as the severity of the event. High variability in costs was observed. Estimating these costs could help clinicians and decision makers a better understanding on the importance of preventing these complications with adequate NVAF treatment.

Conference/Value in Health Info

2015-05, ISPOR 2015, Philadelphia, PA, USA

Value in Health, Vol. 18, No. 3 (May 2015)

Code

PHS33

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Cardiovascular Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×